Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort

Bibliographic Data

ID19594492
AuthorsJocelyn Jansen van Vuuren (0009-0000-9737-8664, Médecins Sans Frontières), Tim Crocker-Buque (0000-0003-0059-7735, London School of Hygiene & Tropical Medicine), Catherine Berry (0000-0001-6363-9387, Médecins Sans Frontières), Dzmitry Viatushka (Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Ruzilya Usmanova (0009-0003-0952-7669, Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Bern-Thomas Nyang’wa (0000-0001-9915-5878, Médecins Sans Frontières), Nargiza Parpieva (0000-0002-0360-1333, Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Irina Liverko (0000-0003-0059-9183, Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Varvara Solodovnikova (0000-0003-1655-4000, Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Animesh Sinha (0000-0001-6785-7322), Animesh A Sinha (0000-0003-3213-7813, Médecins Sans Frontières)
EditorsN Sarita Shah (0000-0001-6069-0857)
Year2024
Volume4
Issue9
Pagese0003057
Publication date2024-09-24
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenuePLOS Global Public Health (JOURNAL)
Journal identifiersISSN: 2767-3375 • E-ISSN: 2767-3375
PublisherPublic Library of Science (PLoS) (PUBLISHER)
DOI10.1371/journal.pgph.0003057
PMID39316626
OpenAlexW4402811341
LanguageEN
References cited14

Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complications in TB patients. This study investigates the co-treatment of MDR/RR-TB and HCV, using data from the TB-PRACTECAL trial. Data were collected as part of the TB-PRACTECAL clinical trial. All participants were screened for HCV at baseline. Participants who were HCV antibody positive and those who were treated for hepatitis C with Direct Acting Antivirals (DAAs) were extracted and compared to overall cohort characteristics. The characteristics of participants concomitantly treated with direct-acting antivirals are described including hepatitis treatment outcomes and adverse events. Among 552 participants from Belarus, Uzbekistan, and South Africa, 24 (4.3%) were HCV antibody positive. Unfavourable TB treatment outcomes were noted in 106/523 (22%) of the HCV-negative, 8/18 (44%) of the HCV-seropositive, and 2/7 (29%) of HCV-confirmed participants treated with DAAs. Of the six participants who received concurrent HCV and MDR/RR TB treatment, three were cured of HCV and three had no post-treatment HCV RNA test, five completed TB treatment and one discontinued treatment due to a severe adverse reaction. Concurrent treatment of MDR-TB and HCV, including in HIV patients, showed promising outcomes with no significant adverse events. The findings support the potential benefits of integrating HCV care into MDR-TB management

Adverse effect · Cohort · Cohort study · Hepatitis C · Hepatitis C virus · Pathology · Rifampicin · Tuberculosis · Virus · Drug-Induced Hepatotoxicity and Protection · Hepatitis C virus research · Medicine · Tuberculosis Research and Epidemiology · Immunology · Internal Medicine

Tools

Open DOIOpen Access